Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 4, 2009, Pages 871-873

  Khachi, Hasanin ^a   O'Connell, R ^a   Ladenheim, D ^b   Orkin, C ^a  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

Drug monitoring; HIV AIDS; Infectious diseases; Mycobacterium tuberculosis; TB

Indexed keywords

LOPINAVIR PLUS RITONAVIR; RIFABUTIN;

ANTIVIRAL THERAPY; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MIXED INFECTION; MYCOBACTERIOSIS;

ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; PYRIMIDINONES; RIFABUTIN; RITONAVIR; SERUM; TUBERCULOSIS; YOUNG ADULT;

EID: 70349464393     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp263     Document Type: Letter

References (6)

1. World Health Organization. Tuberculosis. Fact Sheet No. 104. April 2005. http://www.who.int/mediacentre/factsheets/fs104/en/ (7 January 2007, date last accessed)
2. Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 2001; 164: 7-12.
3. Centres for Disease Control & Prevention. Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR 2004; 53: 37.
4. Centres for Disease Control & Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Recomm Rep 1998; 47 RR20: 1-51.
5. British HIV Association. Treatment Guidelines for TB/HIV Infection February 2005. http://www.bhiva.org/files/file1001577.pdf (7 January 2007, date last accessed).
6. Kwara A, Flanigan TP, Carter EJ. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: Current status. Int J Tuberc Lung Dis 2005; 9: 248-57.